دورية أكاديمية
Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial).
| العنوان: | Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial). |
|---|---|
| المؤلفون: | Baldin, Pamela, Carrasco, Javier, Beniuga, Gabriela, Jouret-Mourin, Anne, Demolin, Gauthier, Roland, Sandrine, D'Hondt, Lionel, Vergauwe, Philippe, Van Daele, Daniel, Mailleux, Marie, Sinapi, Isabelle, De Cuyper, Astrid, BLETARD, Noëlla, Massart, Brigitte, Delos, Monique, Castella, Marie-Laure, van Maanen, Aline, Van den Eynde, Marc |
| المصدر: | Cancers, 14 (5), 1183 (2022-02-24) |
| بيانات النشر: | MDPI, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | bevacizumab, chemotherapy, colorectal liver metastases, histological growth pattern, pathological response, tumoral homogeneity, Oncology, Cancer Research, Human health sciences, Sciences de la santé humaine, Oncologie |
| الوصف: | Retrospective studies reported that preoperative oxaliplatin-based chemotherapy increased pathological response (PR) in patients resected for colorectal liver metastases (CRLM). This multicenter prospective randomized (1/1) phase II trial evaluated PR on resected CRLM after preoperative mFOLFOX6 (arm A) or FOLFIRI (arm B) + bevacizumab. The primary endpoint was the major pathological response rate (MPRR), defined as the percentage of patients presenting CRLMs with mean tumor regression grade (TRG) < 3. Secondary endpoints included safety, progression-free survival (PFS) and overall survival (OS). Out of 65 patients, 57 patients (28 and 29 in arm A/B) were resected for CRLM (one patient with lung metastases). Clinical and treatment characteristics were similar in both arms. One-month postoperative complications were 39.3%/31.0% in arm A/B (p = 0.585). MPRR and complete PR were 32.1%/20.7% (p = 0.379) and 14.3%/0.0% (p = 0.052) in arm A/B, respectively. PFS and OS were not different. Patients with PR among all CRLMs (max TRG ≤ 3; 43.8% of patients) had a lower risk of relapse (PFS: HR = 0.41, 95%CI = 0.204−0.840, p = 0.015) and a tendency towards better survival (OS: HR = 0.34, 95%CI = 0.104−1.114, p = 0.075). The homogeneity of PR was associated with improved PFS/OS. This trial fails to demonstrate a significant increase in MPRR in patients treated with mFOLFOX6-bevacizumab but confirms PR as an important prognostic factor. |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501Test article peer reviewed |
| اللغة: | English |
| العلاقة: | https://www.mdpi.com/2072-6694/14/5/1183/pdfTest; urn:issn:2072-6694 |
| DOI: | 10.3390/cancers14051183 |
| الوصول الحر: | https://orbi.uliege.be/handle/2268/301490Test |
| حقوق: | open access http://purl.org/coar/access_right/c_abf2Test info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsorb.301490 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.3390/cancers14051183 |
|---|